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S U M M A R Y
Introduction: While the rate of vertically transmitted HIV infection has fallen in most regions of Brazil,
there have been no similar decreases in northern and northeastern Brazil.
Objective: The objective of this study was to evaluate the risk factors associated with vertical
transmission in the state of Sergipe in northeastern Brazil.
Methods: This was a retrospective cohort study. We recorded clinic and registry data for all HIV-infected
pregnant women and exposed children diagnosed in Sergipe from 1990 to 2011.
Results: We identiﬁed 538 deliveries and 561 HIV-exposed infants (23 sets of twins). One hundred one
(18.9%) infants were HIV-infected. In the multivariate analysis, infant antiretroviral prophylaxis was a
signiﬁcant protective factor (adjusted odds ratio (aOR) 0.07, 95% conﬁdence interval (CI) 0.01–0.41,
p=0.003). Breastfeeding was marginally associated with an increased odds of perinatal transmission
(aOR 4.52, 95% CI 0.78–26.17, p = 0.092). The attributable risk percentage for breastfeeding over the
study period was 91.0%. Transmission decreased from 91 per 100 live births before 1997 to 2 per 100 in
2011 following the adoption of the prevention protocol.
Conclusion: Transmission declined over the study period. The screening of pregnant women and timely
initiation of prophylaxis and therapy are issues that require further attention.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mother-to-child transmission of HIV (MTCT) is the main route
of transmission through which children acquire HIV-1 infection
worldwide. Approximately 390 000 children worldwide were
newly infected with HIV in 2010, and the vast majority were in
Sub-Saharan Africa.1 In Brazil, 85.8% of AIDS cases in individuals
aged younger than 13 years were found to be due to MTCT,
corresponding to an incidence rate in children 0–5 years old in
2010 of 3.5 per 100 000. HIV prevalence in pregnant women was
most recently estimated to be 0.41%.2 HIV infection in Brazil is
distributed unevenly, both geographically and socioeconomically.3
The southern region, which is more developed and populous and
where the ﬁrst cases were detected in Brazil, has had the greatest
cumulative number of infections, but more recently the less well
developed north and northeastern regions have experienced
increased levels of heterosexual and perinatal transmission.4,5
The annual number of reported AIDS cases in children aged less
than 5 years fell 40.7% between 1998 and 2010 in the south,* Corresponding author.
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decrease in the north and northeast. These rates are important
indicators for monitoring HIV transmission in infants.6
Known risk factors for MTCT include maternal variables
(elevated viral load, symptomatic disease, failure to use antiretro-
viral drugs during pregnancy, smoking), obstetric variables
(vaginal delivery, rupture of membrane >4 h), and neonatal
variables (low birth weight, breastfeeding, prematurity).7–11
Primary strategies to reduce MTCT include maternal and infant
use of antiretrovirals (ARV) to suppress viral replication, caesarean
section before onset of labor or rupture of membranes, and
avoidance of breastfeeding.12,13 Where these combined interven-
tions are available, the risk of MTCT is as low as 1–2%.13–16
Brazil introduced interventions to prevent MTCT in 1996,
beginning with zidovudine prophylaxis, which was subsequently
recommended nationally in 1997 for women who did not meet
clinical, virological, or immunological criteria for the initiation of
antiretroviral therapy (ART).12,17 Starting in 2007, short-term
triple-drug ART was used for prophylaxis in women with CD4 cell
counts of >200 cells/ml and plasma viral loads of >1000 copies/ml.
In 2010 national guidelines were changed to recommend ART for
all pregnant women regardless of CD4 count or other criteria.18
Under all guidelines, in addition to ART or antepartum ARVses. Published by Elsevier Ltd. All rights reserved.
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received oral zidovudine for 6 weeks. Mothers were also counseled
to avoid breastfeeding, and infant formula has been freely available
for replacement feeding since 2002.19
MTCT rates in Brazil were evaluated in a large multicenter study
in 2001, and were found to be between 8.6% in 2000 and 7.1%.14
Subsequent reports have found these rates to vary substantially
across regions and over time, ranging from 12.3% in the
northeastern region to 5.5% in the south in 2004.20 More recently,
rates have been particularly low in areas where effective screening,
prophylaxis, and treatment are available and have recently been
reported to be less than 2% in centers in Porto Alegre and Rio de
Janeiro.5,11 The use of ARV prophylaxis, in particular, has evolved
over the last two decades from zidovudine monotherapy to
combination ARV prophylaxis for women not meeting the criteria
for the initiation of life-long ART.11,13,16,21
We studied the incidence and maternal risk factors associated
with HIV infection in infants in the state of Sergipe in northeastern
Brazil, from 1990 to 2011.
2. Methods
2.1. Overall design
This was a retrospective cohort study of infants born to HIV-
infected women in Sergipe from 1990 to 2011. The start date
corresponds to the diagnosis of the ﬁrst case of HIV in a pregnant
woman in Sergipe.
2.2. Setting
Sergipe is one of nine states in northeastern Brazil, with a
population of 2 068 017 and 34 016 births in 2010.22 Approximately
a third of births occur within the maternity services of Aracaju, the
capital city. Almost all (99.3%) deliveries are in the hospital setting.23
From 1987 to 2011 there were 2930 AIDS cases reported in adults, an
incidence rate of 12.19 per 100 000 per year, and 62 reported in
children less than ﬁve years old, corresponding to an AIDS incidence
of 3.4 per 100 000 per year. Among Brazilian states, Sergipe ranks
twentieth in the AIDS incidence for adults and fourteenth for
children under 5 years of age.6
In all Brazilian states, antenatal care is universal and free of
charge. Antenatal testing for HIV is common in Brazil, and recent
estimates are that 62.3% of women attending antenatal care are
tested.2 In Sergipe, all identiﬁed cases of HIV infection during
pregnancy are referred to receive free ART/prophylaxis for HIV at
CEMAR (the Center of Medical Specialties for HIV/STD/AIDS) in
Aracaju.
2.3. Study subjects
We included all HIV-infected pregnant women and exposed
children diagnosed in Sergipe through December 31, 2011. We
compiled data reported to the national Information System for
Reportable Diseases (SINAN), the national Mortality Information
System (SIM), the state laboratory database (serological and viral
load tests), the ambulatory medical records at the Federal
University of Sergipe and CEMAR, and records from the maternity
services where the majority of HIV-infected women deliver. There
were no other sources from which individuals with HIV infection
could be identiﬁed.
2.4. Variables
Maternal demographic and clinical predictor variables included
area of residence (urban or rural), age, education, vital status,employment status, salary expressed in multiples of the Brazilian
minimum national salary, type of sexual partner (married or
steady partner only, non-marital or steady (i.e., casual) partner
only, or both), number of sexual partners in the past 10 years,
having a child who had previously died of AIDS, transmission
category (current sexual partner with HIV, previous sexual partner
with HIV, lifetime history of injection drug use, or recipient of HIV-
infected blood transfusion), and when HIV was diagnosed (prior to
the current pregnancy, during the current pregnancy, at delivery or
postpartum). We also recorded infant socio-demographic vari-
ables, including sex, birth weight dichotomized as <2500 and
2500 g, birthplace (Aracaju, other part of Sergipe, or other state),
and details of antenatal care and labor, including having received
ARV prophylaxis, having been followed up in the medical system,
and how the diagnosis of HIV was made (virological test,
serological test, postmortem examination). Because our cohort
spanned 22 years, antenatal ARV prophylaxis and treatment
regimens became increasingly effective. We classiﬁed these
regimens as monotherapy, dual therapy, and triple therapy.
Our principal outcome variable was conﬁrmed HIV infection in
children. We deﬁned infection in accordance with the Brazilian
Ministry of Health guidelines as two detectable viral loads or two
positive serological tests and a conﬁrmatory indirect immunoﬂu-
orescence assay or Western blot test by 18 months of age or 1
month after weaning, whichever came later.
2.5. Laboratory tests
Testing protocols were derived from Brazilian national stan-
dards.24 In Sergipe pregnant women are screened with dried blood
spots using an enzyme immunosorbent assay (EIA) (S&S 903,
Symbiosis Diagnostics Ltda, Sa˜o Paulo, Brazil) or immunochroma-
tographic rapid tests (Determine1 HIV-1/2, Abbott Diagnostic
Division, Hoofddorp, The Netherlands; Rapid Check1, Bioman-
guinhos, Rio de Janeiro, Brazil; or UniGold Recombigen1 HIV,
Trinity Biotech plc, Bray, Ireland). Positive tests are conﬁrmed with
two commercial third-generation assays from different manufac-
turers using venous blood samples (Abbott-Axym1, Abbot
Diagnostics Division, Sa˜o Paulo, Brazil; Murex1, Murex Biotech
Ltd, Dartford, England, UK; GENSCREEN1 HIV ag-b, Marnes-la-
Coquette, France; or Q-Prevent HIV 1+2-DBSTM1, Symbiosis
Diagno´stica Ltda, Sa˜o Paulo, Brazil), or, in earlier years, by indirect
immunoﬂuorescence assays (IFA, Biomanguinhos1, Bio-Manguin-
hos, Fiocruz Institute, Rio de Janeiro, Brazil) or Western blot (HIV-
Blot 2.21, Genelabs Diagnostics Pte Ltd, Singapore; or Biorad1,
Cambridge Biotech Corporation, Cambridge, MA, USA). HIV
infection in children less than 18 months of age is determined
by testing for HIV RNA with a lower limit of detection of 50 copies/
ml (Chiron Quantiplex1 version 3bDNA assay, Bayer Corporation,
Emeryville, CA, USA). All the tests are validated and licensed for
commercial use in Brazil, in accordance with local regulations
(Decree #151 of 10-4-2009).
Infants are deﬁned as infected if they have detectable viral loads
in two consecutive tests, one of which must be done after 4 months
of age, or in the case of breastfed infants at 4 months after
breastfeeding ceases. Children 18 months of age are considered
infected if they have two positive antibody tests with a
conﬁrmatory Western blot or IFA. Infants with negative HIV
nucleic acid ampliﬁcation tests and with no symptoms of HIV
infection are considered uninfected, but are followed until two HIV
antibody tests are negative.
2.6. Data analysis
We collected all data on a standard form and then entered them
into a database created using Epi Info 3.5.2 (CDC, Atlanta, GA, USA).
Table 2
Characteristics of HIV-infected pregnant women, Sergipe, Brazil, 1990–2011
Maternal characteristics Na n %
Area of residence 468
Urban 417 89.2
Rural 51 10.8
Age, years 526
<21 22 4.1
21–30 220 41.9
31–50 283 53.8
>50 1 0.2
Education, years 448
None 62 13.9
<8 221 49.4
8 71 15.8
9–10 37 8.2
11 54 12.0
College 3 0.7
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descriptive analyses using SPSS version 13 (SPSS Inc., Chicago, IL
USA) and bivariate analyses using STATA 8.0 (STATA Corp., College
Station, TX, USA). We calculated the relative risk (RR) and 95%
conﬁdence interval (CI). We controlled for possible confounding
variables using a backward Poisson regression, retaining variables
that had a p-value less than 0.05.
2.7. Ethical considerations
We conducted this study in accordance with the principles of
research in Brazil (Resolution 196/96). In the majority of cases,
there was no direct patient contact. In a small number of cases, we
interviewed participants to complete data collection. In these
cases, we obtained informed consent. We did not retain patient
names or medical record numbers in the ﬁnal data sets. The Ethics
and Research Committee of the Federal University of Sergipe
approved the study (registered number 0183.0.107.000-10).
3. Results
Between 1990 and 2011, there were 538 deliveries resulting in
561 HIV-exposed infants (23 sets of twins). Of the 526 infants with
known sex, 247 (47.0%) were male and 279 (53.0%) female. The
mean birth weight was 2994 g (standard deviation (SD) 573 g).
Three hundred fourteen (79.8%) were born in Aracaju. One hundred
twenty-nine (24.3%) were evaluated using virological tests, 94 (17.7%)
using serological tests, 242 (42.7%) using both, and 2 (0.3%) by death
certiﬁcate listing HIV as the cause of death. Of the 561 infants, we
were able to ascertain the outcome for 534 (95.1%) children. Of these,
101 (18.9%) had a conﬁrmed HIV infection, 61 (11.4%) were still under
investigation as of December 31, 2011, and 6 (1.1%) had been stillborn
with no further diagnostic work-up (Table 1).Table 1
Characteristics of HIV-exposed children, Sergipe, Brazil, 1990–2011
Characteristic Na n %
Sex 526
Male 247 47.0
Female 279 53.0
Birth weight, g 323
<2500 52 16.0
2500 271 84.0
Birthplace 393
Aracaju 314 79.8
Interior 76 19.3
Other state 3 0.7
Received infant antiretroviral prophylaxis 397
Yes 322 81.1
No 75 18.9
Follow-up 556
Yes 512 92.0
No 44 8.0
Outcome 534
Infected 101 18.9
Not infected 366 68.5
Still under investigation 61 11.4
Stillborn 6 1.1
Diagnosis 529
Virological 129 24.3
Serological 94 17.7
Both 242 42.7
At deathb 2 0.3
Missing 62 11.7
a The number of infants in each category may not add up to 561 due to missing
information.
b Among the criteria of the Brazilian national case deﬁnition for AIDS, there is one
termed the ‘exceptional death criterion’. This is used when AIDS is diagnosed after
the death of the individual and has been reported on the death certiﬁcate.Thirty-three (5.9%) mothers had died, and three (0.5%) were not
locatable. The majority (89.2%) of mothers lived in urban areas. The
median maternal age was 26 years (interquartile range (IQR) 23–
31 years). Two hundred twenty-one (49.4%) mothers had
completed fewer than 8 years of education, 152 (67.3%) were
unemployed, and 118 (67.8%) had no income. Of the 538 mothers,
267 (91.3%) had been infected sexually; 332 (73.6%) had a single
partner. One hundred seventy-two (35.0%) had been diagnosed
before the current pregnancy, 134 (27.3%) during the current
pregnancy, 100 (20.4%) at delivery, and 85 (17.2%) in the
postpartum period (Table 2). The mean number of pregnancies
was 1.69 (SD 0.93).
In the bivariate analysis, signiﬁcant protective factors associat-
ed with infant infection were antenatal care (RR 0.22, 95% CI 0.14–
0.33), the number of antenatal visits (1–6 visits versus none, RR
0.29, 95% CI 0.18–0.45; and 6 versus none, RR 0.12, 95% CI 0.05–
0.26), HIV testing during antenatal care (RR 0.19, 95% CI 0.11–0.30),Vital status 561
Dead 33 5.9
Alive 525 93.6
Disappeared 3 0.5
Professional status 226
Employed 47 20.8
Unemployed 152 67.3
Self-employed 25 11.0
Retired 2 0.9
Mother’s income, minimum salary unitsb 174
None 118 67.8
<1 9 5.2
1–2 39 22.4
>2 8 4.6
Type of partner 451
Married or steady partner only 332 73.6
Casual partners only 72 16.0
Steady and casual partners 47 10.4
Number of partners in last 10 years 246
1 partner 75 30.5
2–4 partners 121 49.2
>4 partners 50 20.3
Child died of AIDS previously 311
Yes 14 4.5
No 207 66.5
Unknown 90 29.0
Transmission category 288
Current partner with HIV 152 52.8
Previous partner with HIV 115 39.9
Injection drug user 21 7.3
When HIV infection was diagnosed 491
Prior to current pregnancy 172 35.0
During current pregnancy 134 27.3
At delivery 100 20.4
Postpartum 85 17.2
a The number of pregnant women in each category may not add up to 561 due to
missing information.
b Brazilian minimum salary units, US $3732 per year.
Table 3
Cases of perinatally transmitted HIV infection by maternal risk factors, Sergipe, Brazil, 1990–2011
Maternal risk factor Infected, n (%) Uninfected, n (%) Risk ratio 95% conﬁdence interval
Antenatal care (N = 358)
No 40 (46.0) 47 (54.0) Referent
Yes 27 (0.10) 244 (0.90) 0.22 (0.14, 0.33)
Number of visits (N = 358)
None 40 (46.0) 47 (54.0) Referent
1–6 21 (13.2) 138 (86.8) 0.29 (0.18, 0.45)
6 6 (5.4) 106 (94.6) 0.12 (0.05, 0.26)
HIV tested during prenatal care (N = 397)
No 51 (38.6) 81 (61.4) Referent
Yes 19 (7.2) 246 (92.8) 0.19 (0.11, 0.30)
Results of HIV test during antenatal care (N = 265)
HIV-uninfected 2 (40.0) 3 (60.0) Referent
HIV-infected 17 (6.5) 243 (93.5) 0.16 (0.05, 0.53)
Antiretroviral prophylaxis or therapy during antenatal period (N = 393)
No 59 (38.1) 96 (61.9) Referent
Yes 13 (4.9) 225 (95.1) 0.14 (0.08, 0.25)
Gestational age at antiretroviral initiation, months (N = 314)
1–7 months 6 (4.0) 144 (96.0) 0.13 (0.06, 0.29)
8–9 months 52 (31.7) 112 (68.3) Referent
Syphilis test during antenatal care (N = 314)
No 37 (35.6) 67 (64.4) Referent
Yes 21 (10.1) 186 (89.9) 0.29 (0.18, 0.46)
Mode of delivery (N = 406)
Vaginal 39 (21.4) 143 (78.6) Referent
Caesarean 20 (8.9) 204 (91.1) 0.42 (0.25, 0.69)
ARV prophylaxis at delivery (N = 377)
No 58 (50.9) 56 (49.1) Referent
Yes 16 (6.1) 247 (93.9) 0.12 (0.07, 0.20)
Infant ARV prophylaxis (N = 347)
No 43 (64.2) 24 (35.8) Referent
Yes 17 (6.1) 263 (93.9) 0.09 (0.06, 0.16)
Infant breastfed (N = 396)
No 29 (8.8) 301 (91.2) Referent
Yes 48 (72.7) 18 (27.3) 8.28 (5.67, 12.07)
Ever received ART (N = 337)
Never 39 (58.2) 28 (41.8) Referent
Prenatal care only 2 (9.5) 19 (90.5) 0.08 (0.01, 0.54)
Delivery only 5 (8.3) 55 (91.7) 0.13 (0.06, 0.31)
Delivery and PNC 11 (5.8) 178 (94.2) 0.09 (0.05, 0.17)
ARV, antiretroviral; ART, antiretroviral therapy; PNC, prenatal care.
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95% CI 0.05–0.53), ARV prophylaxis or therapy during the antenatal
period (RR 0.14, 95% CI 0.08–0.25), initiation of ARV prophylaxis or
therapy in the seventh month of gestation or earlier (RR 0.13, 95%
CI 0.06–0.25), having a syphilis test during antenatal care (RR 0.29,
95% CI 0.18–0.46), caesarean delivery (RR 0.42, 95% CI 0.25–0.69),
receiving intrapartum ARV prophylaxis (RR 0.12, 95% CI 0.07–
0.20), and the baby receiving ARV prophylaxis (RR 0.09, 95% CI
0.06–0.16). Breastfeeding histories were available for 396 infants.
Overall 66 (16.8%) had been breastfed, including 48 (72.7%) of 77
who were diagnosed with HIV infection but only 18 (5.6%) of 319
who were not (RR 8.28, 95% CI 5.67–12.07) (Table 3).
We examined if any of the 66 breastfed children or their
mothers had ever received ARV prophylaxis. Of the 48 breastfed
infants who were HIV-infected, only two had received postpartum
ARV prophylaxis, and one mother had received intrapartum
prophylaxis. Of the 18 uninfected breastfed children, eight had
received ARV prophylaxis, and four of their mothers had receivedTable 4
Independent risk factors for perinatal HIV infection, Sergipe, Brazil, 1990–2011
Maternal risk factor aOR 95% CI p-Value
Breastfed infant 4.52 (0.78, 26.17) 0.092
Infant received ARV prophylaxis 0.07 (0.01, 0.41) 0.003
Mother received ARV prophylaxis
during antenatal care only
0.13 (0.01, 1.39) 0.092
aOR, adjusted odds ratio; CI, conﬁdence interval; ARV, antiretroviral.prophylaxis (four antepartum and three intrapartum). The risk of
infection for breastfed children who had not received prophylaxis
was 5.6 times higher than for those who had (RR 5.63, 95% CI 1.99–
15.84).
In the multivariate analysis, only breastfeeding was marginally
associated with an increased adjusted odds of perinatal transmis-
sion (adjusted odds ratio (aOR) 4.52, 95% CI 0.78–26.17, p = 0.092).
The use of infant ARV prophylaxis was independently associatedFigure 1. Trends in antiretroviral usage and breastfeeding among HIV-infected
mothers and in HIV transmission to infants, Sergipe, Brazil, 1993–2011.
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0.003) (Table 4), and maternal antepartum prophylaxis was
marginally associated with a decreased odds of transmission
(aOR 0.13, 95% CI 0.01–1.39, p = 0.092).The attributable fraction for
breastfeeding over the study period was 91.0%. The proportion of
HIV-infected women who breastfed their infants fell over the study
period from 91% before 1997 to 2% in 2011, and its decline
narrowly paralleled the decline in HIV-infected infants (r = 0.96).
At the same time, the use of ARV also increased (Figure 1).
4. Discussion
In general, we found a high rate of MTCT in Sergipe, Brazil over
the 22-year study period. This was marginally associated with
breastfeeding, which most likely represents a type II error.
However, when analyzing MTCT over time, we observed a drastic
reduction in rates from 91% to 2% associated with the adoption of
prevention measures, which included not breastfeeding and using
ARV.
The rate of MTCT is high when compared with other Brazilian
studies25,26 and studies done in other countries,27,28 except one
study in three African countries that found a rate of 20.4%.29 In our
study, among infants who were not breastfed, the risk of
transmission was 5.6%, much more in line with the national
experience. However, given that antenatal screening did not
become widespread in Sergipe until 2000 and at delivery only in
2003,18,30 we have likely under-ascertained HIV-infected mothers
who did not transmit HIV to their infants and thus overestimated
transmission rates, especially in earlier years. Thus, in Brazil,
where formula has long been provided free of charge to HIV-
infected mothers, breastfeeding may, in fact, be more of a marker
of poor access to health care in general. In fact, among infected
children who had breastfed, the mother of only one of 48 had
received ARV intrapartum prophylaxis and none had received
antepartum prophylaxis, suggesting that transmission may well
have taken place antepartum or intrapartum.
The risks of postpartum transmission have been well
described.31,32 Extended breastfeeding is responsible for 14% of
cases of HIV-1 in chronically infected mothers, and MTCT may be
as high as 29% if the acute phase of maternal infection occurs
during breastfeeding.10 Another study in a breastfed population
showed that 6.9% of infants who were uninfected at 6 weeks of age
acquired HIV infection by 12 months of age.29 The World Health
Organization (WHO) recommends that HIV-infected women do
not breastfeed in areas where supplemental formula is available.33
In Brazil, infant formula is available to HIV-infected mothers free of
charge.34 It is reassuring to note that while breastfeeding was a
clear risk factor over the 22 years of our study, its importance as a
mode of transmission has declined substantially with fewer than
2% of infected women since 2007 choosing to breastfeed.
We also found that the rate of MTCT declined over the study
period coincident with changes in preventing MTCT (PMTCT)
recommendations. Again, in the earlier years of our cohort, before
antenatal testing became more or less routine in Brazil, infants
with HIV were largely identiﬁed as they became symptomatic. As a
result, there is likely under-ascertainment of exposed but
ultimately uninfected infants, which leads to overestimation of
rates of transmission in the early years of the cohort. Since 2010
when deﬁnitive ART became offered to pregnant women regard-
less of CD4 count,19 the rate has fallen to 4%.
Our study has several limitations. First, because our data were
collected from clinical records, registries, and surveillance
sources, there were missing values. We believe that these missing
values occurred randomly, and hence the principal consequence
of missing data was loss of power. A second limitation, as
discussed above, is under-ascertainment of exposed butultimately uninfected infants in the years before routine antenatal
screening. A third limitation is that 11.4% of infants were still
being evaluated at the time we closed the data set and had to be
excluded from the analysis. Results from these additional infants
could potentially affect some of our results.
Nonetheless, we believe our data are compelling. Breastfeeding
in this population is a marker of either poor access to or utilization
of antenatal care, consistent with the poorer, less educated
population included in our cohort. Vieira et al. found that the
prevalence of HIV infection among pregnant women and the
incidence of vertical transmission were associated with lower
urban quality of residential neighborhood in Brazil.35
Opportunities for PMTCT may be lost at each step of care, from
presentation for antenatal care, through HIV testing and counsel-
ing, to ARV adherence and breastfeeding. These failures may be on
the part of health professionals or local health policy. To improve
engagement, PMTCT programs may need to target this group for
incentives and additional services, including enhanced education
about the value of PMTCT and maternal risk factors for HIV
infection in children. Interventions that improve the engagement
of pregnant women in HIV care and treatment programs are
necessary to achieve the WHO goal of zero mother-to-child HIV
transmission.36
Postpartum transmission remains a risk in Brazil, and the
effects of policy changes such as distributing infant formula for
HIV-exposed infants until 6 months of age with counseling for
mothers18,31 and universal treatment for infected pregnant women
need to be continuously monitored, especially in poorer parts of
the country where signiﬁcant morbidity may accompany formula
feeding if clean water is less available.15 Recent studies from Africa
have demonstrated the protective effect of both long-term
maternal ART and medium-term ARV prophylaxis of mothers or
infants in preventing postpartum transmission,37,38 although at
least one study39 has found an increased risk of adverse pregnancy
outcomes associated with ART in pregnant women.
To eliminate disparities in pediatric HIV infection in Sergipe and
the rest of northeastern Brazil, continued emphasis needs to be
placed on screening pregnant women, facilitating their transition
into HIV care and treatment, providing infant formula or
appropriate prophylaxis through the postpartum period, and
careful monitoring of trends over time.
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